Takashi Owa
Corporate Officer/Principal presso EISAI CO., LTD.
Profilo
Takashi Owa is currently the Chief Executive Officer & Director at H3 Biomedicine, Inc. He also holds the position of Chief Discovery Officer, Head-Japan & Asia Medical at Eisai Co., Ltd.
Posizioni attive di Takashi Owa
| Società | Posizione | Inizio |
|---|---|---|
| EISAI CO., LTD. | Corporate Officer/Principal | 01/04/1991 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| EISAI CO., LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Borsa valori
- Insiders
- Takashi Owa